Embodiments herein relate to a composition comprising an enhanced kava extract, wherein the enhanced kava extract comprises a kava product extracted using a material comprising CO2 and/or ethanol extraction method from a selected part of a kava plant and containing 50% or more of a kavalactone as measured by HPLC, wherein the kava plant is not a wild type kava such that the kava product is safe for human consumption, as well as to the methods of making the composition, and a human edible or drinkable product comprising an enhanced kava extract, and an additive comprising a tetrahydrocannabinol extract, a cannabidiol extract, a hemp extract or combinations thereof. In one embodiment, the enhanced kava extract comprises a kava product extracted using a non-organic solvent.

Embodiments herein relate to a composition comprising an enhanced kava extract, wherein the enhanced kava extract comprises a kava product extracted using a material comprising CO2 and/or ethanol extraction method from a selected part of a kava plant and containing 50% or more of a kavalactone as measured by HPLC, wherein the kava plant is not a wild type kava such that the kava product is safe for human consumption, as well as to the methods of making the composition, and a human edible or drinkable product comprising an enhanced kava extract, and an additive comprising a tetrahydrocannabinol extract, a cannabidiol extract, a hemp extract or combinations thereof. In one embodiment, the enhanced kava extract comprises a kava product extracted using a non-organic solvent.

The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) -alanine or a derivative of -alanine, and (b) at least one agent that inhibits the N-methyl D-aspartate (NMDA) pathway or a pathway which converges downstream with the NMDA pathway. The compositions, formulations, and food or beverage products are useful for enhancing physical performance, reducing -alanine-induced paraesthesia, and improving tolerance and compliance to higher doses of -alanine, thereby reducing the length of time it takes to achieve peak effect of -alanine, and increasing the magnitude of peak effect on physical performance in a human or animal.

The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) -alanine or a derivative of -alanine, and (b) at least one agent that inhibits the N-methyl D-aspartate (NMDA) pathway or a pathway which converges downstream with the NMDA pathway. The compositions, formulations, and food or beverage products are useful for enhancing physical performance, reducing -alanine-induced paraesthesia, and improving tolerance and compliance to higher doses of -alanine, thereby reducing the length of time it takes to achieve peak effect of -alanine, and increasing the magnitude of peak effect on physical performance in a human or animal.

The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) -alanine or a derivative of -alanine, and (b) at least one agent that inhibits the N-methyl D-aspartate (NMDA) pathway or a pathway which converges downstream with the NMDA pathway. The compositions, formulations, and food or beverage products are useful for enhancing physical performance, reducing -alanine-induced paraesthesia, and improving tolerance and compliance to higher doses of -alanine, thereby reducing the length of time it takes to achieve peak effect of -alanine, and increasing the magnitude of peak effect on physical performance in a human or animal.

The present invention relates in some aspects to compositions (e.g., pharmaceutical, nutritional compositions, etc.), formulations, and food or beverage products comprising, consisting essentially of, or consisting of (a) -alanine or a derivative of -alanine, and (b) at least one agent that inhibits the N-methyl D-aspartate (NMDA) pathway or a pathway which converges downstream with the NMDA pathway. The compositions, formulations, and food or beverage products are useful for enhancing physical performance, reducing -alanine-induced paraesthesia, and improving tolerance and compliance to higher doses of -alanine, thereby reducing the length of time it takes to achieve peak effect of -alanine, and increasing the magnitude of peak effect on physical performance in a human or animal.

The present invention provides edible compositions, kits and methods for improving brain function/activity, the composition including at least one alpha brain wave promoting factor including theanine, and at least one neurotransmitter-precursor.

The present invention provides edible compositions, kits and methods for improving brain function/activity, the composition including at least one alpha brain wave promoting factor including theanine, and at least one neurotransmitter-precursor.